Dr. Tomer Mark brings more than a decade of experience as a research physician in the field of hematologic malignancies to his role at Karyopharm. Dr. Mark’s research focus has been on the development of novel therapies for the care of multiple myeloma, including stem cell collection protocols and transplantation conditioning regimens. He has been the principal investigator on multiple early to late phase clinical trials, has authored more than 70 manuscripts in the field of hematology, and he has also contributed to several books pertaining to plasma cell disorders. Dr. Mark has also worked extensively with patient advocacy groups to understand and work to improve the patient experience.
Dr. Mark received his B.S. in Molecular Biophysics and Biochemistry from Yale University and his M.D. with distinction in research from the State University of New York at Stony Brook. He completed his internal medicine residency at Beth Israel Deaconess Medical Center in Boston, Massachusetts and his hematology and medical oncology fellowship at New York Presbyterian Hospital/Weill Cornell Medical Center. During his fellowship, he earned a Masters in Clinical Investigation at the Weil Cornell School of Graduate Sciences. Following fellowship, Dr. Mark served as associate director of the multiple myeloma program at New York Presbyterian hospital and then served as clinical director of the clinical plasma cells disorders and autologous stem cell transplant programs at the University of Colorado – Anschutz Medical Center.